Immix Biopharma prices $125m share offering to fund NXC-201

The Los Angeles CAR-T company raised $125m at $11.00 per share, with J.P. Morgan sole book-runner and backing from Wellington and

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
An open lab freezer with bright cool-toned internal lighting displays two columns of stacked clear plastic containers, each holding distinct white and brown granular layers on metal racks.

Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, raising $125 million in gross proceeds before underwriting discounts and offering expenses. The Nasdaq-listed company said the offering is expected to close on or around 30 September 2026, subject to customary conditions.

J.P. Morgan acted as sole book-running manager for the deal, which drew participation from a mix of new and existing institutional investors. Named participants include Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management, alongside other US biotech-focused funds, suggesting credible institutional conviction in the programme.

Use of proceeds

Immix said it intends to deploy the net proceeds primarily to advance its lead candidate, NXC-201, alongside working capital and general corporate purposes. The company did not provide a detailed breakdown of how proceeds are allocated across clinical activities, nor did it specify an expected cash runway.

NXC-201 is a BCMA-targeted CAR-T cell therapy, sterically optimised with a proprietary CD3 zeta, CD8 hinge and binder configuration that the company describes as a "digital filter" designed to reduce non-specific activation. The therapy is being evaluated in NEXICART-2 (NCT06097832), a US multi-centre study in relapsed/refractory AL Amyloidosis that carries a potentially registrational design. NXC-201 holds FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy status, as well as Orphan Drug Designation from both the FDA and the EMA.

Market and competitive context

AL Amyloidosis is a rare and severe plasma-cell disorder in which misfolded immunoglobulin light chains deposit in cardiac, renal and hepatic tissue, leading to progressive organ failure. The relapsed/refractory setting carries a particularly poor prognosis, and approved treatment options remain limited. BCMA-targeted therapies have demonstrated compelling activity in the related condition of multiple myeloma, where several CAR-T products are now commercially available; Immix is positioning NXC-201 as the leading BCMA-directed approach specifically for AL Amyloidosis, where it faces less direct competition but must generate its own disease-specific evidence base.

The dual FDA designations are meaningful for regulatory and commercial planning. RMAT designation, in particular, enables earlier and more intensive FDA engagement and may support an accelerated approval pathway if the NEXICART-2 readout is sufficiently strong. Investors and clinical observers will be watching that study closely: a registrational design with breakthrough designation in a rare, underserved indication represents a plausible path to approval without a separate Phase 3, though the bar for clinical meaningfulness in organ-based endpoints remains high.

For a company at this stage, a $125 million raise is a substantial financing event, providing meaningful operational leverage to advance NEXICART-2 toward a potential data readout and regulatory submission. The quality of the investor syndicate adds credibility, though the absence of a partnership or licensing deal means Immix retains both the risk and the upside of the programme independently.

Sector

Topic

Geography